Home Conference Coverage ASCO 2019

ASCO 2019

Imaging Increases RCC Diagnoses

Systemic Therapy after IO-VEGF

Immune Checkpoint Therapy plus Cytoreductive Surgery

Immune Checkpoint Inhibitor Response in mRCC

Costs of Episodes of Care in mRCC

First-line IO Combination Therapies in mRCC

Nivolumab plus Ipilimumab versus Sunitinib

Atezolizumab plus Bevacizumab in Renal Cell Carcinoma

CheckMate 920: Efficacy and Safety Interim Results

Pazopanib plus Nivolumab: PAZOREAL Results

Load more
Subscribe to RSS